Open AccessThe impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries
Author(s) -
Sarah Kleijnen,
Teresa Meneses Leonardo Alves,
Kim Meijboom,
Iga Lipska,
Anthonius de Boer,
H.G.M. Leufkens,
Wim Goettsch
Publication year - 2017
Publication title -
quality of life research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 145
eISSN - 1573-2649
pISSN - 0962-9343
DOI - 10.1007/s11136-017-1574-9
Subject(s) - reimbursement , quality of life research , medicine , quality of life (healthcare) , public health , cancer drugs , cancer , quality adjusted life year , environmental health , cost effectiveness , health care , risk analysis (engineering) , nursing , political science , law
The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.